Part ofa series on the
COVID-19 pandemic
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact andrecession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Long COVID Neurological and psychological symptoms Post-exertional malaise Society African diaspora Animals Alzheimer's disease patients Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBTQ community Long-term care Media coverage Mental health Migration Military Notable deaths Other health issues Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Politics Diplomacy Infected leaders Ireland Malaysia New Zealand Russia UK US
COVID-19 portal
v t e

Minhai COVID-19 vaccine (Chinese:康泰民海新冠疫苗), trademarked asKCONVAC (Chinese:可维克;pinyin:Kěwéikè), is aCOVID-19 vaccine developed byShenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd.

In October 2020, KCONVAC started phase I clinical trials with 180 participants in China.^[1] Later, KCONVAC started phase II trials with 1,000 participants in China.^[2]

In May 2021, KCONVAC started phase III trials for global trials with 28,000 participants.^[3]

In August 2021, KCONVAC started phase I trials with 84 participants in China.^[4]

In September, KCONVAC started phase II trials with 480 participants in China.^[5]

‹ Thetemplate below (Graph:Map) is being considered for deletion. Seetemplates for discussion to help reach a consensus. › This graph was using thelegacy Graph extension, which is no longer supported. It needs to be converted to thenew Chart extension.   Full authorization   Emergency authorization   Allowed for travel

On 14 May 2021, the vaccine became the fourth inactivated Chinese Vaccine to be authorised for emergency use.^[6]

Scholia has a profile forMinhai COVID-19 vaccine(Q106522079).

This article about COVID-19 vaccines is astub. You can help Wikipedia byexpanding it.

• v
• t
• e

• Chinese COVID-19 vaccines
• Inactivated vaccines
• Science and technology in China
• COVID-19 vaccine stubs

• Pages using the Graph extension
• Pages with disabled graphs
• Articles with short description
• Short description is different from Wikidata
• Use dmy dates from April 2021
• Articles containing simplified Chinese-language text
• Drugs with non-standard legal status
• Articles without EBI source
• Chemical pages without ChemSpiderID
• Chemical pages without DrugBank identifier
• Articles without KEGG source
• Articles without InChI source
• Articles without UNII source
• Drugs missing an ATC code
• Articles containing unverified chemical infoboxes
• Drugs that are a vaccine
• Articles using infobox templates with no data rows
• All stub articles